Denosumab
Denosumab[2] je ljudsko monoklonalno antitelo za tretman ostioporoze, gubitka koštane mase, koštanih metastaza, multiplog mijeloma, i tumora gigantskih ćelija kostiju.[3][4] Ovaj lek je razvilo biotehnološko preduzeće Amgen.[5] Denosumab je IgG2 monoklonalno antitelo koje je inhibira RANKL ligand.[6][7][8]
| Klinički podaci | |
|---|---|
| Robne marke | Prolia, Ranmark, Xgeva |
| AHFS/Drugs.com | Monografija |
| Identifikatori | |
| CAS broj | 615258-40-7 |
| ATC kod | M05BX04 |
| DrugBank | DB06643 |
| ChEMBL[1] | CHEMBL1237023 
|
| Hemijski podaci | |
| Formula | C6404H9912N1724O2004S50 |
| Mol. masa | 144.7 |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 25,4 dana |
| Farmakoinformacioni podaci | |
| Trudnoća | ? |
| Pravni status | |
| Način primene | Subkutano |
Reference uredi
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ Pageau, Steven C. (2009). „Denosumab”. MAbs 1 (3): 210–215. DOI:10.4161/mabs.1.3.8592. PMC 2726593. PMID 20065634.
- ↑ McClung, Michael R.; Lewiecki, E. Michael; Cohen, Stanley B.; Bolognese, Michael A.; Woodson, Grattan C.; Moffett, Alfred H.; Peacock, Munro; Miller, Paul D. i dr.. (2006). „Denosumab in Postmenopausal Women with Low Bone Mineral Density”. New England Journal of Medicine 354 (8): 821–31. DOI:10.1056/NEJMoa044459. PMID 16495394.
- ↑ Ellis, G. K.; Bone, H. G.; Chlebowski, R.; Paul, D.; Spadafora, S.; Smith, J.; Fan, M.; Jun, S. (2008). „Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer”. Journal of Clinical Oncology 26 (30): 4875–82. DOI:10.1200/JCO.2008.16.3832. PMID 18725648.
- ↑ „Prolia (denosumab)”. Products. Amgen. Arhivirano iz originala na datum 2015-09-29. Pristupljeno 6. 5. 2012.
- ↑ Malan J, Ettinger K, Naumann E, Beirne OR: The relationship of denosumab pharmacology and osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Dec;114(6):671-6. doi: 10.1016/j.oooo.2012.08.439. PMID 23159111
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.
- ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.
Literatura uredi
- Walker, Emily P. (7. 2. 2012.). „Benefit of Bone Drug in Prostate Cancer in Doubt”. MedPage Today.
- Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
- Thomas L. Lemke, David A. Williams, ur. (2007). Foye's Principles of Medicinal Chemistry (6 izd.). Baltimore: Lippincott Willams & Wilkins. ISBN 0-7817-6879-9.
